TrialCancer medicine2023

Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).

Susumu Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.